BioCentury | May 16, 2016
Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes Analyst picks & changes Company Bank Analyst Coverage Opinion Wk chg 5/13 cls ContraFect Corp. (NASDAQ:CFRX) Roth Capital Partners Joseph Pantginis Downgrade Neutral (from buy) -32% $2.20 Pantginis also lowered his...
BC Week In Review | May 9, 2016
Financial News

QLT withdraws private placement

QLT Inc. (TSX:QLT; NASDAQ:QLTI), Vancouver, B.C.   Business: Ophthalmic, Drug delivery   Date announced: 2016-05-02   Type: Private placement   Investors: Broadfin Capital; JW Asset Management LLC ; EcoR1 Capital   Note: QLT terminated its...
BC Week In Review | Dec 7, 2015
Company News

InSite, Sun Pharmaceutical deal

Sun’s Ranbaxy Inc. subsidiary completed its acquisition of ophthalmic company InSite for $0.35 per share or about $48 million (see BioCentury, Sept. 21). InSite Vision Inc. , Alameda, Calif.   Sun Pharmaceutical Industries Ltd. (BSE:524715;NSE:SUNPHARMA), Mumbai,...
BC Week In Review | Nov 2, 2015
Company News

Cipher, Sun Pharmaceutical, Galephar, Allergan deal

Cipher, Galephar and Sun’s Ranbaxy Pharmaceuticals Inc. subsidiary granted Allergan non-exclusive rights to commercialize a generic version of acne drug Absorica Cip-isotretinoin in the U.S., settling a patent suit. Allergan may begin selling its generic...
BC Week In Review | Sep 21, 2015
Company News

InSite, Sun Pharmaceutical deal

Sun’s Ranbaxy Inc. subsidiary will acquire InSite for $0.35 per share or about $48 million. The price is a 3% premium to InSite’s close of $0.34 on Sept. 14, the day before the deal was...
BC Extra | Aug 18, 2015
Politics & Policy

India allocates $267.8M to improve drug regulation

India's Cabinet Committee on Economic Affairs approved a proposal allocating Rs17.5 billion ($267.8 million) over three years to improve government regulation of drugs. The committee is chaired by Prime Minister Shri Narendra Modi. Rs9 billion...
BC Week In Review | Jun 22, 2015
Company News

Epirus, Chemo Group deal

Epirus granted Chemo’s mAbxience subsidiary rights to commercialize BOW015 in Argentina, Chile, Ecuador, Paraguay, Uruguay and Venezuela. BOW015 is a biosimilar version of autoimmune drug Remicade infliximab from Johnson & Johnson (NYSE:JNJ, New Brunswick, N.J.)...
BC Week In Review | Jun 1, 2015
Company News

Teva neurology news

Teva will pay $1.2 billion to settle a 2008 Federal Trade Commission antitrust suit alleging that Cephalon Inc. , which Teva acquired in 2011, paid generic drug manufacturers more than $200 million to drop challenges against...
BC Extra | May 29, 2015
Company News

Teva agrees to $1.2B pay-for-delay settlement

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) will pay $1.2 billion to settle a Federal Trade Commission antitrust suit alleging that Cephalon Inc. , which Teva later acquired, paid generic drug manufacturers more than $200 million to drop...
BC Week In Review | May 4, 2015
Company News

Ranbaxy, Sun Pharmaceutical deal

Sun completed its acquisition of Ranbaxy. Ranbaxy shareholders will receive 0.8 shares of Sun for every share of Ranbaxy held. The transaction values Ranbaxy at Rs352.5 billion ($5.5 billion) based on Sun’s close of Rs1039.85...
Items per page:
1 - 10 of 321
BioCentury | May 16, 2016
Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes Analyst picks & changes Company Bank Analyst Coverage Opinion Wk chg 5/13 cls ContraFect Corp. (NASDAQ:CFRX) Roth Capital Partners Joseph Pantginis Downgrade Neutral (from buy) -32% $2.20 Pantginis also lowered his...
BC Week In Review | May 9, 2016
Financial News

QLT withdraws private placement

QLT Inc. (TSX:QLT; NASDAQ:QLTI), Vancouver, B.C.   Business: Ophthalmic, Drug delivery   Date announced: 2016-05-02   Type: Private placement   Investors: Broadfin Capital; JW Asset Management LLC ; EcoR1 Capital   Note: QLT terminated its...
BC Week In Review | Dec 7, 2015
Company News

InSite, Sun Pharmaceutical deal

Sun’s Ranbaxy Inc. subsidiary completed its acquisition of ophthalmic company InSite for $0.35 per share or about $48 million (see BioCentury, Sept. 21). InSite Vision Inc. , Alameda, Calif.   Sun Pharmaceutical Industries Ltd. (BSE:524715;NSE:SUNPHARMA), Mumbai,...
BC Week In Review | Nov 2, 2015
Company News

Cipher, Sun Pharmaceutical, Galephar, Allergan deal

Cipher, Galephar and Sun’s Ranbaxy Pharmaceuticals Inc. subsidiary granted Allergan non-exclusive rights to commercialize a generic version of acne drug Absorica Cip-isotretinoin in the U.S., settling a patent suit. Allergan may begin selling its generic...
BC Week In Review | Sep 21, 2015
Company News

InSite, Sun Pharmaceutical deal

Sun’s Ranbaxy Inc. subsidiary will acquire InSite for $0.35 per share or about $48 million. The price is a 3% premium to InSite’s close of $0.34 on Sept. 14, the day before the deal was...
BC Extra | Aug 18, 2015
Politics & Policy

India allocates $267.8M to improve drug regulation

India's Cabinet Committee on Economic Affairs approved a proposal allocating Rs17.5 billion ($267.8 million) over three years to improve government regulation of drugs. The committee is chaired by Prime Minister Shri Narendra Modi. Rs9 billion...
BC Week In Review | Jun 22, 2015
Company News

Epirus, Chemo Group deal

Epirus granted Chemo’s mAbxience subsidiary rights to commercialize BOW015 in Argentina, Chile, Ecuador, Paraguay, Uruguay and Venezuela. BOW015 is a biosimilar version of autoimmune drug Remicade infliximab from Johnson & Johnson (NYSE:JNJ, New Brunswick, N.J.)...
BC Week In Review | Jun 1, 2015
Company News

Teva neurology news

Teva will pay $1.2 billion to settle a 2008 Federal Trade Commission antitrust suit alleging that Cephalon Inc. , which Teva acquired in 2011, paid generic drug manufacturers more than $200 million to drop challenges against...
BC Extra | May 29, 2015
Company News

Teva agrees to $1.2B pay-for-delay settlement

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) will pay $1.2 billion to settle a Federal Trade Commission antitrust suit alleging that Cephalon Inc. , which Teva later acquired, paid generic drug manufacturers more than $200 million to drop...
BC Week In Review | May 4, 2015
Company News

Ranbaxy, Sun Pharmaceutical deal

Sun completed its acquisition of Ranbaxy. Ranbaxy shareholders will receive 0.8 shares of Sun for every share of Ranbaxy held. The transaction values Ranbaxy at Rs352.5 billion ($5.5 billion) based on Sun’s close of Rs1039.85...
Items per page:
1 - 10 of 321